From: Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations
Drug treatment | IC50 (μM) qRT-PCR | Fold reduction of IC50 (single/combined) |
---|---|---|
Niclosamide-ivermectin | ||
 Niclosamide | 0.043 |  |
  Niclosamide + ivermectin 2.4 μM | ND | ND |
  Niclosamide + ivermectin 1.2 μM | ND | ND |
  Niclosamide + ivermectin 0.6 μM | 0.018 | 2.399 |
  Niclosamide + ivermectin 0.3 μM | 0.022 | 1.955 |
 Ivermectin | 1.27 |  |
  Ivermectin + niclosamide 0.09 μM | ND | ND |
  Ivermectin + niclosamide 0.0045 μM | ND | ND |
  Ivermectin + niclosamide 0.0225 μM | 0.313 | 4.06 |
  Ivermectin + niclosamide 0.01125 μM | 0.660 | 1.92 |
Niclosamide-chloroquine | ||
 Niclosamide | 0.043 |  |
  Niclosamide + chloroquine 1.7 μM | ND | ND |
  Niclosamide + chloroquine 0.85 μM | ND | ND |
  Niclosamide + chloroquine 0.425 μM | 0.013 | 3.308 |
  Niclosamide + chloroquine 0.2125 μM | 0.029 | 1.483 |
 Chloroquine | 0.89 |  |
  Chloroquine + niclosamide 0.09 μM | ND | ND |
  Chloroquine + niclosamide 0.0045 μM | ND | ND |
  Chloroquine + niclosamide 0.0225 μM | 0.249 | 3.57 |
  Chloroquine + niclosamide 0.01125 μM | 0.531 | 1.68 |
Ivermectin-chloroquine | ||
 Ivermectin | 1.27 |  |
  Ivermectin + chloroquine 1.7 μM | ND | ND |
  Ivermectin + chloroquine 0.85 μM | ND | ND |
  Ivermectin + chloroquine 0.425 μM | 0.515 | 2.47 |
  Ivermectin + chloroquine 0.2125 μM | 0.821 | 1.55 |
 Chloroquine | 0.89 |  |
  Chloroquine + ivermectin 2.4 μM | ND | ND |
  Chloroquine + ivermectin 1.2 μM | ND | ND |
  Chloroquine + ivermectin 0.6 μM | 0.315 | 2.83 |
  Chloroquine + ivermectin 0.3 μM | 0.514 | 1.73 |